Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01941043 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
A Phase 2 study of Major Depressive Disorder, sponsored by Avalo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,357
- Enrollment target
- 20
- Study locations
NCT01941043 is a Phase 2 study of Major Depressive Disorder that has completed, run by Avalo Therapeutics. The registered enrollment target is 1,357 participants, above the 372-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (265% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01941043, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Avalo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,357 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective serotonin- or serotonin-norepinephrine reuptake inhibitors (SSRI or SNRI). The study population will be enriched for subjects that would benefit most from rapid onset, those with recent active suicidal ideation, but not a risk to themselves or others and are deemed appropriate for an out-patient study with careful safety surveillance. This will allow the study to focus on the antidepressant effects of CERC-301 but also explore effects on suicidal ideation. To explore rapid onset, the primary endpoint will be at 7 days, but effects over the 28 days of treatment will be examined as a secondary endpoint.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CERC-301
Study Locations (20)
California
- ProScience Research Group - Culver City
- Collaborative NeuroScience Network, Inc. - Garden Grove
- Behavioral Research Specialists - Glendale
- Synergy Clinical Research Center - National City
- Pacific Clinical Trials, LLC - Oakland
- Southern CA Psychiatrists - Oceanside
- Artemis Institute for Clinical Research - San Diego
Florida
- Clinical Neuroscience Solutions - Jacksonville
- Scientific Clinical Research, Inc. - North Miami
- Clinical Neuroscience Solutions - Orlando
New York
- Bioscience Research - Mount Kisco
- The Medical Research Network - New York
- Finger Lakes Clinical Research - Rochester
Georgia
- Atlanta Center for Medical Research - Atlanta
- Northwest Behavioral Research Center - Marietta
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Arizona TMS Therapy Center - Phoenix
Illinois
- Chicago Psychiatry Associates - Chicago
Maryland
- Sheppard Pratt Health System - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,357 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01941043
The ClinicalTrials.gov registry entry for NCT01941043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,357 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 372-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (265% higher). The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01941043 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01941043 about?
NCT01941043 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment". The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective serotonin- or serotonin-norepinephrine reuptake inhibitors (SSRI or SNRI)....
What is the current status of trial NCT01941043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,357 participants. The study started on 2013-11. Estimated completion is 2014-10.
What conditions does trial NCT01941043 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT01941043?
The interventions under investigation include: Placebo (OTHER), CERC-301 (DRUG).
Who is sponsoring clinical trial NCT01941043?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01941043 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.